Blueprint Medicines (NASDAQ:BPMC) Sets New 52-Week High at $111.02

Blueprint Medicines Co. (NASDAQ:BPMC - Get Free Report) shares reached a new 52-week high on Tuesday . The stock traded as high as $111.02 and last traded at $108.48, with a volume of 25147 shares changing hands. The stock had previously closed at $108.05.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on BPMC. Stifel Nicolaus boosted their target price on shares of Blueprint Medicines from $120.00 to $130.00 and gave the company a "buy" rating in a research report on Friday, April 26th. JMP Securities boosted their target price on shares of Blueprint Medicines from $114.00 to $125.00 and gave the company a "market outperform" rating in a research report on Friday, May 3rd. Citigroup upped their price target on shares of Blueprint Medicines from $65.00 to $76.00 and gave the stock a "sell" rating in a research report on Friday, May 3rd. StockNews.com upgraded shares of Blueprint Medicines from a "sell" rating to a "hold" rating in a research report on Friday, May 3rd. Finally, Stephens assumed coverage on shares of Blueprint Medicines in a research report on Tuesday. They issued an "overweight" rating and a $140.00 price target for the company. Two analysts have rated the stock with a sell rating, six have issued a hold rating, nine have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $102.65.

Blueprint Medicines Trading Down 2.4 %

The stock's 50 day moving average is $93.31 and its 200-day moving average is $83.52. The company has a debt-to-equity ratio of 0.67, a quick ratio of 3.61 and a current ratio of 3.76.

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last announced its quarterly earnings data on Thursday, February 15th. The biotechnology company reported ($1.82) EPS for the quarter, beating the consensus estimate of ($2.04) by $0.22. Blueprint Medicines had a negative net margin of 102.15% and a negative return on equity of 193.48%. The firm had revenue of $71.96 million during the quarter, compared to analyst estimates of $67.34 million. During the same period last year, the firm posted ($2.65) EPS. Blueprint Medicines's revenue was up 85.5% on a year-over-year basis. On average, equities research analysts predict that Blueprint Medicines Co. will post -5.15 earnings per share for the current fiscal year.

Insider Buying and Selling at Blueprint Medicines

In other Blueprint Medicines news, Director Jeffrey W. Albers sold 25,073 shares of the stock in a transaction that occurred on Wednesday, March 20th. The stock was sold at an average price of $87.28, for a total transaction of $2,188,371.44. Following the completion of the transaction, the director now owns 176,050 shares of the company's stock, valued at $15,365,644. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, Director Jeffrey W. Albers sold 25,073 shares of the stock in a transaction that occurred on Wednesday, March 20th. The stock was sold at an average price of $87.28, for a total value of $2,188,371.44. Following the completion of the sale, the director now owns 176,050 shares of the company's stock, valued at $15,365,644. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Ariel Hurley sold 1,834 shares of the stock in a transaction that occurred on Thursday, May 2nd. The shares were sold at an average price of $103.88, for a total value of $190,515.92. Following the completion of the sale, the insider now directly owns 14,913 shares of the company's stock, valued at approximately $1,549,162.44. The disclosure for this sale can be found here. Insiders sold 104,123 shares of company stock valued at $9,554,679 over the last quarter. 3.88% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Blueprint Medicines

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Covestor Ltd grew its position in Blueprint Medicines by 9,700.0% in the first quarter. Covestor Ltd now owns 294 shares of the biotechnology company's stock worth $28,000 after acquiring an additional 291 shares during the period. Headlands Technologies LLC grew its position in Blueprint Medicines by 105.2% in the first quarter. Headlands Technologies LLC now owns 667 shares of the biotechnology company's stock worth $63,000 after acquiring an additional 342 shares during the period. Compass Wealth Management LLC purchased a new position in Blueprint Medicines in the fourth quarter worth approximately $69,000. Natixis purchased a new position in Blueprint Medicines in the first quarter worth approximately $73,000. Finally, PNC Financial Services Group Inc. grew its position in Blueprint Medicines by 63.4% in the third quarter. PNC Financial Services Group Inc. now owns 848 shares of the biotechnology company's stock worth $43,000 after acquiring an additional 329 shares during the period.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.